MEDIGENE AG

AVIMOTIN

pharmaceutical preparations for the prevention, treatment and diagnosis of diseases, in particular medicines, vaccines, serums and test kits comprised of small molecules, liposomes, aptamers, nucleic acids, peptides, proteins, protein conjugates, antibodies, enzymes and enzyme preparations, hormones, hormone analogues, attenuated viruses, virus-like particles and plant extracts, in particular for oral, topical, intravenous and subcutaneous administration, all for the prevention, treatment and diagnosis of tumour precursors, benign and malignant tumours, in particular warts, genital warts, neurona1 tumours, glioma, astrocytoma, colon carcinoma, ovarian carcinoma, cervical cancer, prostate carcinoma, basa1 cell carcinoma, squamous cell carcinoma, melanoma, Kaposi's sarcoma, breast cancer, head and neck carcinomas, hepatocellular carcinoma, bronchial carcinoma, pancreatic tumours and renal tumours, autoimmune disorders, in particular rheumatoid arthritis, polyarthritis, Crohn's disease, lupus erythematosus and multiple sclerosis, rheumatic disorders, in particular rheumatoid arthritis, polychondritis, Bechterew's disease, fibromyalgia and lupus erythematosus, skin diseases, in particular warts, genital warts, Bowen's disease, actinic keratosis, seborrhoeic keratosis, psoriasis, dermatitis, eczema, acne, rosacea and herpes;The wording AVIMOTIN has no meaning in a foreign language.;

ECONOMISER

The stylized letter i in the mark is red and blue, the lower part being blue and the upper part, i.e., the dot being red and the colors, red, blue and black are claimed as features of the mark.;In the statement, Column 1, line 14, media; should be deleted, and, media, should be inserted. In the statement, Column 2, after line 11, The stylized letter i in the mark is red and blue, the lower part being blue and the upper part, i.e., the dot being red and the colors, red, blue and black are claimed as features of the mark. should be inserted.;MEDICINES, DIAGNOSTIC AND THERAPEUTIC PREPARATIONS FOR ANIMALS AND HUMANS FOR THE TREATMENT OF CARDIAC DISEASES, METABOLIC DISEASES AND DIABETES, AMINO ACIDS FOR MEDICAL AND VETERINARY PURPOSES;In the statement, column 2, after line 11. The stylized letter i in the mark is red and blue, the lower part being blue and the upper part, i.e., the dot being red and the colors, red, blue and black are claimed as features of the mark.;The stylized letter i in the mark is red and blue, the lower part being blue and the upper part ie, the dot being red and the colors red, blue and black are claimed as features of the mark. is/are claimed as a feature of the mark.;TEST KITS CONSISTING PRIMARILY OF CHEMICAL AND BIOCHEMICAL COMPONENTS AND BIOTECHNOLOGICAL COMPONENTS, NAMELY NUCLEIC ACIDS, PROTEINS, VIRUSES, ANTIBODIES, ANTIGENS, SERUMS, PLASMAS, [MEDIA;] *MEDIA,* BUFFERS, CELLS, ANTIBIOTICS, HORMONES, REAGENTS, AND NEGATIVE CONTROL MATERIAL AND TUBES, CUPS, APPLICATORS, SYRINGES, MULTIPLE WELL PLATES, FLAKES, BOTTLES, AND PETRI DISHES FOR SCIENTIFIC AND RESEARCH USE; DIAGNOSTIC PREPARATIONS AND AMINO ACIDS FOR SCIENTIFIC AND RESEARCH USE;

ENDOTAG

79020593;Medicines for humans and animals in the form of serums and diagnostic preparations for medical purposes and therapeutic use, namely, medicines for treating tumorous diseases such as gliomas, carcinomas of the colon, ovarian carcinomas, cervical carcinomas, carcinomas of the prostate, melanomas, basal cell carcinomas, actinic keratosis, breast cancers, bone cancers, brain cancers, colon cancers, endocrine system cancers, gastrointestinal cancers, gynaecological cancers, head and neck cancers, leukemias, lung cancers, lymphomas, metastases, myelomas, pediatric cancers, penile cancers, sarcomas, skin cancers, testicular cancers, thyroid cancers, urinary tract cancers, pleural cancers, neuronal cancers, mesotheliomas, astrocytomas, oligodendrogliomas, meningiomas, neurofibromas, glioblastomas, ependymomas, schwannomas, neurofibrosarcomas, neuroblastomas, pituitary gland cancers, cancers of the hypophysis, medulloblastomas, renal cell carcinomas, pancreatic cancers, gastric cancers, bladder cancers, liver cancers, prostate cancer, fibrosarcomas, squamous cell carcinomas, neuroectodermal cancers, hodgkin's lymphomas, non-hodgkin's lymphomas, hepatomas, epidermal carcinomas, or medicines for treating chronic inflammatory diseases such as rheumatoid arthritis, autoimmune diseases, allergies, multiple sclerosis; medicines for stimulating wound healing; medicines for treating eye diseases and arteriosclerosis; medicines for treating cardiovascular illnesses, namely, hyperlipidaemia, coronary heart diseases and cardiac insufficiency; medicines for treating skin diseases, namely, warts, genital warts and herpes; excluding medicines for enemas and for the preparation of a coloscopy;

ENDOTAG

76677125;Services of a molecular biological or pharmaceutical laboratory, namely, research and development in the field of human medical and veterinary medical diagnostics and therapy by means of molecular biological, genetic engineering, biotechnological, chemical and pharmaceutical methods; development of pharmaceutical preparations and medicines; screening, namely testing of chemical or biological compounds for pharmaceutically effective properties; development of diagnostic testing processes and test kits;

EUROPTIM

In the statement, Column 1, line 5, ONKOLOGIELOCHHAMER should be deleted, and, ONKOLOGIE LOCHHAMER should be inserted, and, In the statement, Column 1, line 9, SERUMS,THERAPEUTIC should be deleted, and, SERUMS, THERAPEUTIC should be inserted, and, In the statement, Column 2, line 12, 12-21-2011 should be deleted, and, 12-31-2011 should be inserted.;MOLECULAR BIOLOGICALLY DEVELOPED MEDICINES, SERUMS, THERAPEUTIC PREPARATIONS FOR ANIMALS AND HUMANS FOR THE TREATMENT OF CARDIAC DISEASES, SKIN DISEASES, CANCER, DIABETES AND OBESITY; MOLECULAR BIOLOGICALLY DEVELOPED TEST KITS FOR CLINICAL AND MEDICAL LABORATORY USE, COMPRISED OF BIOCHEMICAL AND BIOTECHNOLOGICAL COMPONENTS FOR THE IDENTIFICATION, ANALYSIS AND VALIDATION OF TARGET GENES AND/OR THE IDENTIFICATION OF NEW PHARMACEUTICALLY ACTIVE COMPOUNDS FOR HUMAN MEDICAL AND VETERINARY MEDICAL DIAGNOSTIC AND THERAPY PURPOSES; AND MOLECULAR BIOLOGICALLY DEVELOPED DIAGNOSTIC PREPARATIONS FOR CLINICAL AND MEDICAL LABORATORY USE;

I

The mark is comprised of a stylized I in red and blue, where the top oval (the dot) is red, and the bottom oval is blue.;MEDICAMENTS FOR THE TREATMENT OF CARDIAC, CANCER, METABOLIC AND DERMATOLOGIC DISEASES OR DISORDERS IN HUMAN BEINGS AND ANIMALS; SERUMS AND RECOMBINANT PROTEINS AS VACCINES AGAINST CANCER AND INFECTIOUS DISEASES; TEST KITS CONTAINING ANTIBODIES, ENZYMES, DNA AND BIOCHEMICAL SOLUTIONS FOR THE TESTING OF CARDIAC DISEASES, SUCH AS CONGESTIVE HEART FAILURE, AND CANCER DISEASES, SUCH AS CERVICAL AND OVARIAN CANCER, MELANOMA AND OTHER EPITHELIAL TUMORS AND DERMATOLOGIC DISEASES OR DISORDERS, SUCH AS GENITAL WARTS, IN HUMAN BEINGS AND ANIMALS; DIAGNOSTIC AND THERAPEUTIC REAGENTS, SUCH AS ANTIBODIES, DNA, ENZYMES AND BIOLOGICAL SOLUTIONS FOR CLINICAL MEDICAL LABORATORY USE IN THE FIELD OF HUMAN AND VETERINARY MOLECULAR BIOLOGY, GENETIC ENGINEERING AND BIOENGINEERING;MOLECULAR BIOLOGY SERVICES, NAMELY, RESEARCH AND DEVELOPMENT IN THE FIELDS OF HUMAN MEDICAL AND VETERINARY MEDICAL DIAGNOSTICS AND THERAPY USING MOLECULAR BIOLOGICAL, GENETIC ENGINEERING AND BIOTECHNOLOGICAL METHODS, AND IN THE FIELD OF SCREENING COMPOUNDS WITH PHARMACEUTICAL PROPERTIES, AND DEVELOPMENT OF TESTING PROCESSES AND TEST KITS;

ILTREX

MOLECULAR BIOLOGICALLY DEVELOPED MEDICINES, SERUMS, THERAPEUTIC PREPARATIONS FOR ANIMALS AND HUMANS FOR THE TREATMENT OF CARDIAC DISEASES, SKIN DISEASES, CANCER,DIABETES AND OBESITY; MOLECULAR BIOLOGICALLY DEVELOPED TEST KITS FOR CLINICAL AND MEDICAL LABORATORY USE, COMPRISED OF BIOCHEMICAL AND BIOTECHNOLOGICAL COMPONENTS FOR THE IDENTIFICATION, ANALYSIS AND VALIDATION OF TARGET GENES AND/OR THE IDENTIFICATION OF NEW PHARMACEUTICALLY ACTIVE COMPOUNDS FOR HUMAN MEDICAL AND VETERINARY MEDICAL DIAGNOSTIC AND THERAPY PURPOSES; AND MOLECULAR BIOLOGICALLY DEVELOPED DIAGNOSTIC PREPARATIONS FOR CLINICAL AND MEDICAL LABORATORY USE;

LOMILIN

Pharmaceutical products for topical, intra-vaginal and/or intra-anal application, namely, pharmaceutical preparations for use in treating the skin diseases of warts, verruca vulgaris, verruca plantaris, verruca plana, flat condylomata, mosaic-type warts, butcher's warts, anogenital warts, condylomata accuminata, hyperplasia of the epidermis, recalcitrant cutaneous warts, herpes infection, genital and anal herpes infection, shingles, Molluscum contagiosum, mycosis, mycosis fungoides, tinea, tinea pedis, pigmentation disorders, hyperpigmentation, hypopigmentation, vitiligo, melasma, atypical/displastic/melanocytic nevi, sun-damaged skin, removal of tattoos, psoriasis, neurodermitis, dermatitis, atopic dermatitis, cutaneous atopy, eczema, lichen planus, cutaneous lupus erythematosus, skin ulcers, rosacea, precancerous and cancerous lesions, increased proliferation of skin cells, actinic keratosis, actinic cheilitis, keloids, lentigo, hemangioma, Epidermodysplasia verruciformis, Bowen's disease, Bowenoid papulosis, basal cell carcinoma, intraepithelial squamous cell carcinoma, melanoma, and other skin cancers, neoplasias, cervical dysplasia, cervical intraepithelial neoplasias, anal intraepithelial neoplasias, vulvar intraepithelial neoplasia, penile cancer, vulvovaginal cancer, anal carcinoma, cervical carcinoma, cutaneous T-cell lymphoma, alopecia, vulvodynia, keloid and hypertrophic scars, post surgical excision on scar cosmesis, hyperkeratosis, seborrhea, Darier's disease, porokeratosis of mibelli, ichthyosis, xerosis, dartroud disthesis, acne, nasal papilloma, oral papilloma, focal epithelial hyperplasia, laryngeal papilloma, recurrent respiratory papillomatosis and conjunctival papilloma;

MEDIGENE

IN THE STATEMENT, COLUMN 1, BEFORE LINE 1, MEDIGENE AG, (GERMANY CORPORATION), MARTINSRIED, MUNICH, GERMANY, BY CHANGE OF NAME FROM, SHOULD BE INSERTED.;medicaments for the treatment of [ cardiac, ] cancer [ and metabolic ] diseases in human beings [ and animals ] ; [serums and recombinant proteins as vaccines against cancer and infectious diseases; test kits containing antibodies, enzymes, DNA and biochemical solutions for the testing of cardiac diseases, such as congestive heart failure, and cancer diseases, such as cervical and ovarian cancer, melanoma and other epithelial tumors in human beings and animals; diagnostic and therapeutic reagents, such as antibodies, DNA, enzymes and biochemical solutions for clinical medical laboratory use in the field of human and veterinary molecular biology, genetic engineering and bioengineering];laboratory research and development of testing methods in the fields of human [ and veterinary ] molecular biology, genetic engineering and bioengineering, screening for pharmaceutically effective compounds;

MEDIGENE

Medicines for humans and animals, except venous-therapeutics, namely, medicines for treating [ cardiovascular and vascular diseases, ] dermatological disorders and diseases, [ precancerous diseases, benign and malignant tumors, infectious diseases, allergic and asthmatic diseases, neurodegenerative diseases, autoimmune diseases, diseases of the respiratory tract, gastrointestinal diseases, blood disorders, aging-associated diseases, genetic disorders, metabolic disorders, musculoskeletal disorders and eye diseases, vaccines for treating cardiovascular and vascular diseases, dermatological disorders and diseases, precancerous diseases, benign and malignant tumors, infectious diseases, allergic and asthmatic diseases, neurodegenerative diseases, autoimmune diseases, diseases of the respiratory tract, gastrointestinal diseases, blood disorders, aging-associated diseases, genetic disorders, metabolic disorders, musculoskeletal disorders and eye diseases; serums, namely, immune serums for passive vaccination for treating infectious diseases, diagnostic test kits comprising antibodies, antibody fragments, serums, soluble monoclonal T-cell receptors, peptides, peptide-analogues, enzymes, liposomes, dyes, radioactively labeled substances, for the purpose of testing, diagnosing and monitoring cardiovascular and vascular diseases, dermatological disorders and diseases, precancerous diseases, benign and malignant tumors, infectious diseases, allergic and asthmatic diseases, neurodegenerative diseases, autoimmune diseases, diseases of the respiratory tract, gastrointestinal diseases, blood disorders, aging-associated diseases, genetic disorders, metabolic disorders, musculoskeletal disorders and eye diseases; proteins, proteinconjugates, peptides, enzymes and enzyme-preparations, antibodies, T-cell-proteins, attenuated viruses, virus-like particles, liposomes, ] herbal extracts, components of low molecular weight, all for use as medicines [, vaccines and parts of medical diagnostic test kits for treating, testing, diagnosing and monitoring all diseases mentioned above ];MEDICINE GENE;

MEDIGENE

Services in the field of molecular biology, namely, research and development in the field of medical and veterinary diagnosis and treatment using molecular biological, biotechnological and genetic methods, and in the field of screening for compounds and tumor antigens with pharmaceutical properties; development of test methods and test kits in the field of molecular biology; development of adoptive T cell therapy; development of DC vaccines; development of cellular tumor therapy; development of tumor markers; development of diagnostic and therapeutic antibodies; genetic and biological cell analyses; development of individualized medicine, development of treatment plans and therapy adapted for individual patients; all the foregoing being for scientific purposes;

MEDIGENE

The mark consists of the wording MEDIGENE in stylized script, where the letter I is comprised of two oval shapes.;Pharmaceutical and veterinary preparations, namely, cellular preparations for the treatment of tumours/neoplastic diseases, hematological tumors, more specifically leukemias or lymphomkas, solid tumors; Pharmaceutical T-cell preparations and dendritic cell preparations for the treatment of cancer and use in immunotherapy; medical compositions in the nature of pharmaceutical preparations for the treatment of hematological and solid tumors, tumor precursors; Test kits for diagnostic preparations for medical purposes for determining the type and/or existence of a tumor in a patient consisting primarily of soluble T-cell receptors; test kits for diagnostic preparations for medical purposes for determining the type and/or existence of a tumor in a patient consisting primarily of genetically modified cells; Test kits for diagnostic preparations for medical purposes for determining the type/existence of a tumor in a patient consisting of a composition of antibodies, soluble T-cell receptors and genetically modified cells; Diagnostic and therapeutic preparations for medical purposes being mixtures of therapeutically active cells in a suitable medium, in particular produced using molecular biological, biotechnological and genetic methods;Color is not claimed as a feature of the mark.;Cell analyses in the nature of medical analysis services for diagnostic and treatment purposes provided by medical laboratories; Medical and veterinary medical services, in particular extracting of blood and/or tissue samples and analysis and evaluation relating thereto; Individualized medicine in the nature of medical services; medical services specifically, development of treatment plans for the treatment of tumors and/or neoplastic diseases, hematopoietic tumors, solid tumors; physical therapy adapted for individual patients;Services in molecular biology, in particular research and development in the field of medical and veterinary diagnosis and treatment using molecular biological, biotechnological and genetic methods, and in the field of screening for compounds with pharmaceutical properties; Development of test methods and test kits; Development of adoptive T cell therapy; Development of DC vaccines; Development of cellular tumour therapy; Development of tumour markers; Development of diagnostic and therapeutic antibodies;